AXT1003
- Generic Name
- AXT1003
Study of AXT-1003 in Subjects with Advanced Malignant Tumors.
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Axter Therapeutics (Beijing) Co., Ltd
- Target Recruit Count
- 78
- Registration Number
- NCT06484985
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳Hunan Cancer Hosptial, Changsha, China
🇨🇳Fujian Cancer Hospital, Fuzhou, China
Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Axter Therapeutics (Beijing) Co., Ltd
- Target Recruit Count
- 1
- Registration Number
- NCT05965505
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
🇨🇳Beijing Cancer Hospital, Beijing, China
🇨🇳West China Hospital, Sichuan University, Chengdu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath